Irish drug house Elan Corp. is using Sard Verbinnen & Co and FTI Consulting to bolster its takeover defense in the aftermath of a $6.6B offer from New York-based Royalty Pharma, an investment management company.

Full Story | Subscribe to O'Dwyer's | Free E-Newsletter on PR